Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial
Year: 2026
Type: article
Source: Annals of Oncology
Institutions: Vall d'Hebron Institute of Oncology, The University of Texas MD Anderson Cancer Center, Samsung Medical Center, Massachusetts General Hospital, University of California, Los Angeles, Peking University Cancer Hospital, Istituto Oncologico Veneto, Fujian Provincial Cancer Hospital, University Kebangsaan Malaysia Medical Centre, National University of Malaysia, Fudan University Shanghai Cancer Center, The Christie Hospital, The Christie NHS Foundation Trust, Bristol-Myers Squibb (Switzerland), Bristol-Myers Squibb (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Roche, Sanofi, European Association for Cancer Research, American Society of Clinical Oncology, Memorial Sloan-Kettering Cancer Center, Baylor University, University of Pittsburgh, Taiho Pharmaceutical, Mirati Therapeutics, BeiGene, Cancer Research UK, Fundación Científica Asociación Española Contra el Cáncer, Universidad de Navarra, Sociedad Española de Oncología Médica, Servier, Novartis Farmacéutica, Deutschen Konsortium für Translationale Krebsforschung, INCLIVA Instituto de Investigación Sanitaria, Genentech, Chugai Pharmaceutical, Cancer Center, University of Colorado, Baylor University Medical Center, Ignyta, HORIZON EUROPE Framework Programme, National Cancer Institute, Cilag
OpenAlex ID: W7168730212
